IL-18 revives dysfunctional CAR-T cells.

IF 17.5 1区医学 Q1 ONCOLOGY

Trends in cancer Pub Date : 2025-07-07 DOI:10.1016/j.trecan.2025.06.008

Yan-Ruide Li, Yichen Zhu, Lili Yang

引用次数: 0

Abstract

IL-18-armored chimeric antigen receptor (CAR)-engineered T (18.CAR-T) cells have demonstrated enhanced antitumor efficacy in lymphoma patients refractory to conventional CAR-T therapy. Unraveling the mechanisms behind this potent enhancement and mitigating associated toxicities could unlock a new era of next-generation CAR-T therapies with superior effectiveness and broader clinical impact.

查看原文本刊更多论文

IL-18可以激活功能失调的CAR-T细胞。

il -18装甲嵌合抗原受体（CAR）工程T细胞（18.CAR-T）在常规CAR-T治疗难治性淋巴瘤患者中显示出增强的抗肿瘤疗效。揭示这种有效增强和减轻相关毒性背后的机制可能开启下一代CAR-T疗法的新时代，这些疗法具有卓越的有效性和更广泛的临床影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Trends in cancer Medicine-Oncology

CiteScore

28.50

自引率

0.50%

发文量

138

期刊介绍： Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine. Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.